Breast Neoplasm Female
Conditions
Keywords
neo-adjuvant chemotherapy, pathological complete response, Neoadjuvant Therapy, Capecitabine, Chemotherapy, Adjuvant
Brief summary
This study evaluates whether sequential neo-adjuvant chemotherapy plus surgery followed by Capecitabine could achieve additional benefits over traditional postoperative chemotherapy. In the study group, patients that do not achieve pathological complete response(pCR) will receive sequential neo-adjuvant chemotherapy followed by Capecitabine. In the control group, patients will be treated with postoperative adjuvant chemotherapy.
Detailed description
Neo-adjuvant chemotherapy(NAC) is a standard treatment for locally advanced breast cancer(LABC). By down-staging LABC, NAC is able to make inoperable cases operable as well as to make breast conserving surgery an option again for some patients.Neo-adjuvant chemotherapy is more and more widely used in operable breast cancer since it provides critical information on chemotherapy response. However, only 15% to 20% of the patients can benefit from Neo-adjuvant chemotherapy and achieve pCR. Although we obtained the information chemotherapy response for the rest of the patients who received Neo-adjuvant chemotherapy, there are still controversies on how the information will be used for further treatment. Therefore, it is a problem that needs resolving how these patients can benefit from the information Neo-adjuvant chemotherapy provides and whether Neo-adjuvant chemotherapy can replace conventional adjuvant chemotherapy at all. Our study aims to make Neo-adjuvant chemotherapy benefit more patients. Registered patients in stage Ⅰ- Ⅲ A breast cancer is randomly split into two groups(study group and control group).In the study group, patients achieving pCR will be followed up for 5 years while patients that do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine for 8 cycles after surgery. On the other hand, patients in the control group will accept surgeries and conventional adjuvant chemotherapies. Follow-up study will last 5 years. DFS and OS will be compared between the two groups. This study provides an important basis and methods for the further treatment of patients after neo-adjuvant chemotherapy. It discusses whether neo-adjuvant chemotherapy could replace conventional adjuvant chemotherapy and become a new standard for breast cancer treatment.
Interventions
PROCEDURENeo-adjuvant Chemotherapy
A preoperative chemotherapy based on anthracyclines and taxanes.
DRUGCapecitabine
Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
Sponsors
First Hospital of China Medical University
The Second Affiliated Hospital of Harbin Medical University
Qingdao University
First Affiliated Hospital Xi'an Jiaotong University
Baotou Cancer Hospital
The First Hospital of Jilin University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Pathologically confirmed unilateral invasive carcinoma (all pathological types); 2. No gross or microscopic residual tumor after resection; 3. Clinical stage Ⅰ-stage Ⅲ A, no absolute surgical contraindications; 4. Eastern Cooperative Oncology Group(ECOG) score ≤1; 5. Accepting adjuvant chemotherapy within 15 days after surgery; 6. No peripheral neuropathy; 7. Normal bone marrow and organ functions: 1. Bone marrow function: ANC≥1500/mm3，PLT≥100000/mm3，HGB≥8g/dl 2. Renal function: serum creatinine≤1.5 times the upper limit of normal(ULN), Liver function: total bilirubin ≤1.5 times the upper limit of normal，AST≤2.5 times the upper limit of normal，alanine aminotransferase(ALT)≤2.5 times the upper limit of normal 3. Cardiac function:LVEF≥50% 8. Signed informed consent form.
Exclusion criteria
1. Patients with the history of oral fluorouracil chemotherapy or Chinese medicine treatment; 2. Patients with organ dysfunction: 1. Renal function: serum creatinine\>1.5 times the upper limit of normal 2. Liver function: total bilirubin\>1.5 times the upper limit of normal，AST\>1.5 times the upper limit of normal, alanine aminotransferase(ALT)\>1.5 times the upper limit of normal or alkaline phosphatase (ALP) \>2.5 times the upper limit of normal 3. Cardiac function：LVEF\<50%; 3. Human epidermal growth factor receptor-2(HER-2) positive patients who cannot receive Herceptin treatment with a left ventricular ejection fraction(LVEF) less than 55%; 4. Patients allergic to docetaxel, capecitabine, epirubicin and cyclophosphamide; 5. Patients with severe systemic disease and/or uncontrollable infections; 6. Patients with previous malignancies, including contralateral breast cancer; 7. Patients with severe cardiovascular and cerebrovascular disease(i.e. Unstable angina, chronic cardiac failure, uncontrollable high blood pressure of \>150/90 mmhg, myocardial infarction and cerebrovascular accident) history within 6 months before randomization; 8. Pregnant or lactating women. 9. Patients who have cognitive or psychological impairment as well as cannot understand the test program or stand side effects, which will result in a suspension of the trial program and follow-up; 10. Patients without personal freedom or independent civil capacity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival(DFS) | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival(OS) | 5 years |
Countries
China
Contacts
Primary ContactFan Zhimin, Professor
Backup ContactHan Bing, Professor
Outcome results
None listed